Receptor-mediated mitophagy regulates EPO production and protects against renal anemia
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA664995 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR12692692_1.fastq.gz | Fastqsanger.gz | |||
| SRR12692692_2.fastq.gz | Fastqsanger.gz | |||
| SRR12692693_1.fastq.gz | Fastqsanger.gz | |||
| SRR12692693_2.fastq.gz | Fastqsanger.gz | |||
| SRR12692694_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 12 |
Similar Datasets
Project description:Erythropoietin (EPO) drives erythropoiesis and is secreted mainly by the kidney upon hypoxic or anemic stress. The paucity of EPO production in renal EPO-producing cells (REPs) causes renal anemia, one of the most common complications of chronic nephropathies. Although mitochondrial dysfunction is commonly observed in several renal and hematopoietic disorders, the mechanism by which mitochondrial quality control impacts renal anemia remains elusive. In this study, we showed that FUNDC1, a mitophagy receptor, plays a critical role in EPO-driven erythropoiesis induced by stresses. Mechanistically, EPO production is impaired in REPs in Fundc1-/- mice upon stresses, and the impairment is caused by the accumulation of damaged mitochondria, which consequently leads to the elevation of the reactive oxygen species (ROS) level and triggers inflammatory responses by up-regulating proinflammatory cytokines. These inflammatory factors promote the myofibroblastic transformation of REPs, resulting in the reduction of EPO production. We therefore provide a link between aberrant mitophagy and deficient EPO generation in renal anemia. Our results also suggest that the mitochondrial quality control safeguards REPs under stresses, which may serve as a potential therapeutic strategy for the treatment of renal anemia.
2021-05-07 | GSE158361 | GEO
Project description:Erythropoietin (EPO) drives erythropoiesis and is secreted mainly by the kidney upon hypoxic or anemic stress. The paucity of EPO production in renal EPO-producing cells (REPs) causes renal anemia, one of the most common complications of chronic nephropathies. Although mitochondrial dysfunction is commonly observed in several renal and hematopoietic disorders, the mechanism by which mitochondrial quality control impacts renal anemia remains elusive. In this study, we showed that FUNDC1, a mitophagy receptor, plays a critical role in EPO-driven erythropoiesis induced by stresses. Mechanistically, EPO production is impaired in REPs in Fundc1-/- mice upon stresses, and the impairment is caused by the accumulation of damaged mitochondria, which consequently leads to the elevation of the reactive oxygen species (ROS) level and triggers inflammatory responses by up-regulating proinflammatory cytokines. These inflammatory factors promote the myofibroblastic transformation of REPs, resulting in the reduction of EPO production. We therefore provide a link between aberrant mitophagy and deficient EPO generation in renal anemia. Our results also suggest that the mitochondrial quality control safeguards REPs under stresses, which may serve as a potential therapeutic strategy for the treatment of renal anemia.
| S-EPMC8121547 | biostudies-literature
Project description:Since iron deficiency anemia (IDA) is one of the most common diseases in worldwide, it is an essential issue to prevent and to treat the IDA in public healthcare system. However, the precise adaptive responses and their mechanisms of the hematopoietic system induced by iron deficient state are not fully understood. In this study, low iron diet conditions which induce sever iron deficiency anemia in mice were established. Transcriptome analyses in erythroblasts under normal or iron deficient states were performed to describe the pathological details of IDA. Under iron deficient state, extensive gene expression changes and mitophagy disorder were induced during the terminal maturation of erythroblasts. These findings provide a new insight into pathophysiology and molecular biology of IDA and the function of iron as a coordinator of gene expression networks in erythrocyte maturation.
2016-12-14 | GSE77694 | GEO
Project description:We identify and analyse in detail a specific Sca-1-positive cell population that increases after treatment with the anaemia drug roxadustat and is capable to support Epo production in mice
2021-05-14 | GSE150669 | GEO
Project description:Renal Epo producing Sca-1+ interstitial cells are increased in number after treatment with the anemia drug roxadustat
| PRJNA633129 | ENA
Project description:Mitophagy is a major quality control pathway that removes unwanted or dysfunctional mitochondria, and plays an essential role in vascular health. Here we show that MCM8 expression is significantly decreased in children with Kawasaki disease (KD) who developed coronary artery aneurysms. Mechanistically, we discover that nitric oxide (NO) signaling promotes TRIM21 mediated MCM8 ubiquitination, which disrupts its interaction with MCM9 and promotes its cytosolic export. In the cytosol, MCM8 relocates to the mitochondria pore forming proteins and promotes their ubiquitination by TRIM21. In addition, MCM8 directly recruits LC3 via its LIR motif and initiates mitophagy. This suppresses mitochondrial DNA-mediated activation of type I interferon via cGAS and STING. Mice that are deficient in Mcm8, Trim21, Nos2, or reconstituted with the East-Asian specific MCM8-P276 variant develop more severe coronary artery vasculopathy in the Lactobacillus casei extract-induced KD model. Collectively, the data suggest that MCM8 protects vascular health in the KD setting.
2023-06-29 | GSE235994 | GEO
Project description:Although chromatin architecture has been established in a variety of cell and tissue types, chromatin contacts’ dynamics in response to hormone stimulation has yet to be fully elucidated. Using the unique anemia-inducing strain of the Friend virus (FVA) murine model system, we show that there are transcriptional and epigenetic changes in response to erythropoietin within an invariant chromatin domain organization. There is an acute transcriptional response, as seen by genes with significant differential RNA polymerase II occupancy. Additionally, we find that YY1 is highly dynamic in response to Epo stimulation and these binding locations are not shared with CTCF. Using HiChIP, which combines Hi-C and ChIP methodologies, we identified enhancer-promoter interactions mediated by H3K27ac and YY1, revealing a subset of invariant chromatin loops. Together, these findings offer new insights into Epo-mediated gene regulation through chromatin organization.
2020-09-28 | GSE142004 | GEO
Project description:Although chromatin architecture has been established in a variety of cell and tissue types, chromatin contacts’ dynamics in response to hormone stimulation has yet to be fully elucidated. Using the unique anemia-inducing strain of the Friend virus (FVA) murine model system, we show that there are transcriptional and epigenetic changes in response to erythropoietin within an invariant chromatin domain organization. There is an acute transcriptional response, as seen by genes with significant differential RNA polymerase II occupancy. Additionally, we find that YY1 is highly dynamic in response to Epo stimulation and these binding locations are not shared with CTCF. Using HiChIP, which combines Hi-C and ChIP methodologies, we identified enhancer-promoter interactions mediated by H3K27ac and YY1, revealing a subset of invariant chromatin loops. Together, these findings offer new insights into Epo-mediated gene regulation through chromatin organization.
2020-09-28 | GSE142005 | GEO
Project description:Although chromatin architecture has been established in a variety of cell and tissue types, chromatin contacts’ dynamics in response to hormone stimulation has yet to be fully elucidated. Using the unique anemia-inducing strain of the Friend virus (FVA) murine model system, we show that there are transcriptional and epigenetic changes in response to erythropoietin within an invariant chromatin domain organization. There is an acute transcriptional response, as seen by genes with significant differential RNA polymerase II occupancy. Additionally, we find that YY1 is highly dynamic in response to Epo stimulation and these binding locations are not shared with CTCF. Using HiChIP, which combines Hi-C and ChIP methodologies, we identified enhancer-promoter interactions mediated by H3K27ac and YY1, revealing a subset of invariant chromatin loops. Together, these findings offer new insights into Epo-mediated gene regulation through chromatin organization.
2020-09-28 | GSE142003 | GEO
Project description:Erythropoiesis is a crucial part in hematopoietic system, while facing disruptions from various diseases conditions. Anemia and blood shortages has become global challenges, with current finite pharmacological options like EPO or glucocorticoids having limitations, especially in genetic anemias like Diamond-Blackfan anemia (DBA), calling for novel candidates in stimulating the erythropoiesis. We designed the primary human hematopoietic stem and progenitor cells (HSPCs) chemicals screening system in erythropoiesis and unexpectedly discovered a BRAF inhibitor, effectively against BRAFV600E mutant cancers, delaying erythroid differentiation while promoting progenitors’ proliferation. Further research demonstrated its efficacy in cytokine-restricted conditions and in samples from erythroid disorder patients. Mechanistically, BRAF inhibitors paradoxically activated the RAF-MEK-ERK/MAPK pathway. Unlike oncogenic BRAFV600E impaired hematopoiesis and erythropoiesis via AP-1 hyperactivation, BRAF inhibitors minimally affected HSPCs self-renewal and differentiation. In vivo studies further exhibited BRAF inhibitors' potential to enhance human hematopoiesis and erythropoiesis in severe immunodeficient mouse models and alleviate anemia symptoms in Rpl11 haploinsufficiency DBA models and other anemia models. This discovery sheds light on the MAPK pathway's role in hematopoiesis, making BRAF inhibitors a novel clinically therapeutic choice in improving hematopoietic reconstitution and the recovery of anemias like DBA.
2024-12-03 | GSE275226 | GEO